Actively Recruiting
Assessment of the Type I IFN Response in the Nasal Cavity During Respiratory Viral Infections in a Geriatric Department
Led by Hospices Civils de Lyon · Updated on 2026-05-22
1140
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the response of type I interferons (IFN-I) in the nasal cavity during respiratory viral infections in older adults. The study focuses on patients admitted to geriatric wards and participants from the REFIPA study who have tested positive for respiratory viruses such as influenza, SARS-CoV-2, and respiratory syncytial virus (RSV). The goal is to improve diagnosis of viral infections by measuring the IFN-I response, which may indicate active viral replication and help distinguish between current and past infections, especially in elderly populations where this response may be affected by age or other health conditions. The study evaluates the IFN-I score calculated from nasopharyngeal swab samples collected for routine virus detection. These samples, already taken for standard clinical care or as part of the REFIPA study, are analyzed to measure the IFN-I response without requiring additional sample collection. The IFN-I score is then compared to first-line PCR tests for influenza, SARS-CoV-2, and RSV to assess its ability to detect active respiratory viral infections. The study includes two groups: geriatric patients admitted for suspected infection and REFIPA study participants diagnosed with PCR-confirmed infections. Participants contribute by providing nasopharyngeal swab samples taken during their clinical care or REFIPA study visits. Researchers will analyze these samples to evaluate the IFN-I response and compare it to standard PCR test results. The main outcome is the diagnostic performance of the IFN-I score in detecting respiratory viral infections. This study aims to enhance viral infection diagnosis in elderly patients, helping to optimize care and infection control in geriatric wards. Participation involves one-time analysis of existing samples, with no additional procedures required.
CONDITIONS
Brief Title
Assessment of the Type I IFN Response in the Nasal Cavity During Respiratory Viral Infections in a Geriatric Department
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted to a geriatric ward
- Participants diagnosed with a PCR-positive respiratory viral infection from a nasopharyngeal swab taken as part of the REFIPA study
- Nasopharyngeal swab sample available with at least 500 �b5L volume from standard clinical care testing
You will not qualify if you...
- Patient objects to the use of their data in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - One time
Participants have nasopharyngeal swab samples taken as part of routine clinical care or previous study participation to evaluate the Type I IFN response and detect respiratory viral infections.
1 visit (sample collection as part of clinical care or prior study)
Duration - Up to study completion
Participants are observed based on available data from clinical care and prior study samples without additional visits or interventions.
No additional visits
Trial Site Locations
Total: 1 location
1
Hôpital Lyon Sud
Lyon, France, 69310
Actively Recruiting
Research Team
S
Sophie S TROUILLET-ASSANT, PHD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here